227 related articles for article (PubMed ID: 32425524)
1. Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy.
Wang W; Fan J; Zhu G; Wang J; Qian Y; Li H; Ju J; Shan L
Int J Nanomedicine; 2020; 15():2921-2933. PubMed ID: 32425524
[TBL] [Abstract][Full Text] [Related]
2. Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.
Shan L; Liu M; Wu C; Zhao L; Li S; Xu L; Cao W; Gao G; Gu Y
Int J Nanomedicine; 2015; 10():5571-91. PubMed ID: 26366078
[TBL] [Abstract][Full Text] [Related]
3. Delivery of baicalein and paclitaxel using self-assembled nanoparticles: synergistic antitumor effect in vitro and in vivo.
Wang W; Xi M; Duan X; Wang Y; Kong F
Int J Nanomedicine; 2015; 10():3737-50. PubMed ID: 26045664
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel/IR1061-Co-Loaded Protein Nanoparticle for Tumor-Targeted and pH/NIR-II-Triggered Synergistic Photothermal-Chemotherapy.
He L; Qing F; Li M; Lan D
Int J Nanomedicine; 2020; 15():2337-2349. PubMed ID: 32308385
[TBL] [Abstract][Full Text] [Related]
5. Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting.
Yin T; Wu Q; Wang L; Yin L; Zhou J; Huo M
Mol Pharm; 2015 Aug; 12(8):3020-31. PubMed ID: 26086430
[TBL] [Abstract][Full Text] [Related]
6. Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Lv Y; Xu C; Zhao X; Lin C; Yang X; Xin X; Zhang L; Qin C; Han X; Yang L; He W; Yin L
ACS Nano; 2018 Feb; 12(2):1519-1536. PubMed ID: 29350904
[TBL] [Abstract][Full Text] [Related]
7. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.
Zhang W; Li C; Shen C; Liu Y; Zhao X; Liu Y; Zou D; Gao Z; Yue C
Drug Deliv; 2016 Sep; 23(7):2575-2580. PubMed ID: 26056720
[TBL] [Abstract][Full Text] [Related]
8. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
Xu C; Liu W; Hu Y; Li W; Di W
Theranostics; 2020; 10(7):3325-3339. PubMed ID: 32194871
[TBL] [Abstract][Full Text] [Related]
9. Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.
Hou H; Zhang D; Lin J; Zhang Y; Li C; Wang Z; Ren J; Yao M; Wong KH; Wang Y
J Agric Food Chem; 2018 Nov; 66(44):11812-11822. PubMed ID: 30339011
[TBL] [Abstract][Full Text] [Related]
10. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer.
Wu J; Wang Q; Dong X; Xu M; Yang J; Yi X; Chen B; Dong X; Wang Y; Lou X; Xia F; Wang S; Dai J
Theranostics; 2021; 11(8):3710-3724. PubMed ID: 33664857
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.
Duan XC; Yao X; Zhang S; Xu MQ; Hao YL; Li ZT; Zheng XC; Liu M; Li ZY; Li H; Wang JR; Feng ZH; Zhang X
Int J Nanomedicine; 2019; 14():195-204. PubMed ID: 30636872
[TBL] [Abstract][Full Text] [Related]
12. Self-Assembly of pH-Labile Polymer Nanoparticles for Paclitaxel Prodrug Delivery: Formulation, Characterization, and Evaluation.
Levit SL; Gade NR; Roper TD; Yang H; Tang C
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291475
[TBL] [Abstract][Full Text] [Related]
13. A paclitaxel prodrug with bifunctional folate and albumin binding moieties for both passive and active targeted cancer therapy.
Shan L; Zhuo X; Zhang F; Dai Y; Zhu G; Yung BC; Fan W; Zhai K; Jacobson O; Kiesewetter DO; Ma Y; Gao G; Chen X
Theranostics; 2018; 8(7):2018-2030. PubMed ID: 29556370
[TBL] [Abstract][Full Text] [Related]
14. Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy.
Yang J; Lv Q; Wei W; Yang Z; Dong J; Zhang R; Kan Q; He Z; Xu Y
Drug Deliv; 2018 Nov; 25(1):807-814. PubMed ID: 29553858
[TBL] [Abstract][Full Text] [Related]
15. l-Peptide functionalized dual-responsive nanoparticles for controlled paclitaxel release and enhanced apoptosis in breast cancer cells.
Niu S; Bremner DH; Wu J; Wu J; Wang H; Li H; Qian Q; Zheng H; Zhu L
Drug Deliv; 2018 Nov; 25(1):1275-1288. PubMed ID: 29847177
[TBL] [Abstract][Full Text] [Related]
16. Probing the fluorination effect on the self-assembly characteristics,
Wang X; Yang B; Li L; Liu T; Zuo S; Chi D; He Z; Sun B; Sun J
Theranostics; 2021; 11(16):7896-7910. PubMed ID: 34335971
[No Abstract] [Full Text] [Related]
17. Development of redox-responsive theranostic nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of tumor.
Yang X; Shi X; Ji J; Zhai G
Drug Deliv; 2018 Nov; 25(1):780-796. PubMed ID: 29542333
[TBL] [Abstract][Full Text] [Related]
18. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
[No Abstract] [Full Text] [Related]
19. Paclitaxel and betulonic acid synergistically enhance antitumor efficacy by forming co-assembled nanoparticles.
Wang J; Qiao W; Zhao H; Yang X
Biochem Pharmacol; 2020 Dec; 182():114232. PubMed ID: 32979350
[TBL] [Abstract][Full Text] [Related]
20. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
